Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.49 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492808 | 0.93 | CNR1 (0.59) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL1492774 | 0.91 | WNT3A (0.54) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL1492842 | 0.91 | WNT3A (0.54) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL1492669 | 0.83 | PSEN1 (0.49) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL27809668 | 0.79 | ROCK2 (0.55) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492709 | 0.79 | WNT3A (0.50) | MAPK1WNT3APSEN1PSEN2APH1B | |
| SCHEMBL1492730 | 0.79 | MAPK1 (0.60) | MAPK1WNT3APSEN1PSEN2APH1B | |
| SCHEMBL1492752 | 0.78 | PSEN1 (0.47) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL1493028 | 0.77 | PSEN1 (0.68) | MAPK1WNT3ACNR1PSEN1PSEN2 | |
| SCHEMBL1493726 | 0.77 | MAPK1 (0.53) | MAPK1WNT3APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAPK1 3550/4885WNT3A 2435/4885CNR1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.